anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a fat emulsion, excellent in stability in sterilization, preservation and mixing with other transfusion solutions and useful for supplying nutriments, and a method for producing the aforementioned fat emulsion. CONSTITUTION:A fat emulsion is obtained by including 0.01-5.0wt./vol.% content of an emulsifying agent and regulating the average particle diameter to >=0.17mum. Furthermore this method for producing the fat emulsion of this invention is to produce the aforementioned fat emulsion by the coexistence of glycerol and/or glucose in preparing the emulsion. According to this invention, the average particle diameter of the fat emulsion is regulated to <=0.17mum and the stability of the fat emulsion is remarkably improved. A good emulsified state can simultaneously be kept in mixing with other transfusion solutions. The fat emulsion having the above-mentioned characteristics can simply and surely be prepared according to the method for production of this invention.
The growth of industrialization growth the risk of vanadium (V) contamination. The objective of this study was to examine the impact of 200 µg L- 1 VCI3 -induced toxicity as well as the potential protective effect of 187.5 mg L- 1 and 375 mg L- 1Hypericum perforatum (H. perforatum) extracts against this toxicity on the Allium cepa (A. cepa) model organism. For this purpose, a series of investigations were conducted on the growth physiology alterations (germination percentage, root elongation, weight gain), cytogenetic alterations (mitotic index, micronucleus, chromosomal aberrations), biochemical alterations (malondialdehyde, superoxide dismutase, catalase) and defects in meristematic tissue in A. cepa. In addition, the phenolic compound content of H. perforatum extract was determined by the LC/MS-MS method. V application negatively affected all the investigated parameters and caused a serious phytotoxic and genotoxic effect as well as oxidative stress in A. cepa. Conversely, no statistical difference was observed between the parameters of the groups treated with H. perforatum extract and those of the control group. The administration of H. perforatum extract combined with V resulted in a notable enhancement in germination percentage, root elongation, weight gain, mitotic index value, chlorophyll a level and chlorophyll b level. Additionally, it led to a reduction in micronucleus and chromosomal aberrations frequencies, as well as meristematic tissue defects. Furthermore, LC/MS-MS analysis demonstrated that H. perforatum extract contains phenolic compounds, including catechin, epicatechin, quercetin, oleuropein and rutin, which confer antioxidant properties to the extract. The study provided clear evidence that H. perforatum extract attenuates the toxic effects of V in A. cepa, which can be attributed to its high content of bioactive phenols. The findings of the study indicate that H. perforatum extract may serve as a protective natural agent for daily use against heavy metal toxicity.
Patients receive riluzole PO BID on days 1-14. Patients also receive oxaliplatin via IVPB over 2 hours, leucovorin calcium IVPB over 2 hours, and bevacizumab IVPB over 30 minutes on day 1 and fluorouracil via IV push over 5 minutes and then IV continuously over 46 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
BIODEGRADABLE POLYMERIC DRUG DELIVERY     SYSTEM WITH ADJUVANT ACTIVITY Abstract of the Disclosure An antigen delivery system utilizing a biodegradable polymer with good mechanical properties in combination with a material stimulating the immune system.  The material having adjuvant activity may be polymer degradation products or an adjuvant which is contained within or bound to the polymer.  In one embodiment, the polymer is formed from tyrosine dipeptides.          Poly(CTTH-iminocarbonate) is a preferred tyrosine dipeptide polymer for constructing implantable delivery systems for antigenic material.  The polymer is not an adjuvant in itself but degrades into products which stimulate the immune system.  The tyrosine dipeptide can also be used as a conventional adjuvant.          The advantages of the system are that a polymer can be used to form a biodegradable integral structure which is useful as both an implantable source of an antigen or other biologically active compound and as a control means for the rate of release of the biologically active compound, wherein the result is sustained, relatively constant delivery of antigen with simultaneous stimulation of the immune response.
this study included a prospective, multicenter, randomized controlled clinical trial.

About 60 patients will be recruited in the randomized clinical trial. Participants will be randomly divided into experimental group (n=30) and control group (n=30). The patients in the experimental group will receive Brucea javanica oil emulsion injection combined with the best supportive treatment, based on the NCCN best palliative treatment guidelines (2022. V1). The patients in the control group received the best supportive treatment based on the NCCN's best palliative treatment guidelines (2022. V1). The primary end point was PFS (progression-free survival). The research protocol was approved by the relevant ethics committee. The research was conducted in accordance with the Helsinki Declaration and good clinical practice guidelines. The patient has written informed consent to participate in the trial.
<P>PROBLEM TO BE SOLVED: To provide a medicine effective for the treatment of inflammatory bowel disease or irritable bowel syndrome.  <P>SOLUTION: A water-soluble polysaccharide extract is obtained by extracting rice bran with hot water, separating insoluble matter by filtration, and processing the filtrate with glucoamylase to decompose starch. An enzyme composite is obtained from a precipitate produced by adding ammonium sulfate to a culture filtrate formed by culturing Lentinus edodes belonging to Basidiomycetes. A biological decoration is given to the water-soluble polysaccharide extract by mixing the enzyme composite with the water-soluble polysaccharide extract, allowing them to react with each other at a pH of 4.5 for 30 to 60 minutes, and further allowing them to react with each other at a pH of 6.0 for 30 to 60 minutes. The product is, for example, disinfected, sterilized, and concentrated for use as a liquid medicine of a bowl disease treating agent.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Subjects first received CDFR0209 each morning in a fasting state for 7 days. After a washout period of 14 days, they then received Losec 40 mg in a fasting state each morning for 7 days.
Therapeutic effect and safety of 10 days of decitabine. Acute myeloid leukemia,no acute promyelocytic leukemia.
Angiotensin, through its type-1 receptor (AT1), is a major inducer of inflammation and oxidative stress, contributing to several diseases. Autoimmune processes have been involved in neurodegeneration, including Parkinson's disease (PD). AT1 autoantibodies (AT1-AA) enhance neurodegeneration and PD, which was related to increased neuronal oxidative stress and neuroinflammation. However, the effect of AT1-AA on α-synuclein aggregation, a major factor in PD progression, has not been studied. In cultures of dopaminergic neurons, we observed that AT1-AA promote aggregation of α-synuclein, as AT1-AA upregulated major mechanisms involved in the α-synuclein aggregation process such as NADPH-oxidase activation and intracellular calcium raising. The results further support the role of AT1 receptors in dopaminergic neuron degeneration, and several recent clinical studies observing the neuroprotective effects of AT1 receptor blockers.
The invention belongs to the field of medicines, and provides an application of aspirin in a medicine for treating skin injury caused by high toxic compounds such as mustard gas. Skin is an important organ with the largest exposed area of human body, and symptoms such as skin erosion are caused after mustard poisoning, and no specific therapeutic drug is aimed at the mustard at the present stage. Experiments prove that aspirin can effectively improve mustard skin injury on animals. And further found that the administration of aspirin has a critical effect on the treatment of mustard. In animal experiments, aspirin is directly smeared on the wound surface of mustard gas to obtain no good treatment effect, and after the aspirin is prepared into soluble microneedles, the aspirin shows good treatment effect. The invention provides a new thought for treating the damage of the mustard gas and also provides a prospect medicine for curing the damage of the mustard gas.
Participants will complete 60 min of treadmill exercise on day 1 (15:15-16:15). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
The safety and effectiveness of AIRSUPRA have not been established in pediatric patients. A limited number of pediatric patients (4 to 17 years of age) were enrolled in the efficacy trial (MANDALA) to evaluate AIRSUPRA to reduce the risk of severe asthma exacerbations. The primary efficacy endpoint was time to first severe asthma exacerbation. Results showed there were 9 patients with severe exacerbation events in 34 patients 12 to 17 years of age treated with AIRSUPRA 180 mcg/160 mcg and 7 patients with severe exacerbation events in 34 patients treated with albuterol (AS MDI) [HR 1.44 (0.54, 3.87)]. There were 11 patients with severe exacerbation events in 41 patients 4 to 11 years of age treated with albuterol/budesonide (AS-BD MDI) 180 mcg/80 mcg and 10 in the 42 patients 4 to 11 years of age treated with AS MDI [HR: 1.09 (0.46, 2.56)]. These data are inadequate to make a determination regarding the safety or effectiveness of AIRSUPRA or AS-BD 180 mcg/80 mcg in pediatric patients 4 to 17 years of age [see Clinical Studies (14)]. 

Controlled clinical studies have shown that ICS agents, including budesonide, one of the components of AIRSUPRA, may cause a reduction in growth velocity in pediatric patients. The effects of long-term treatment of pediatric patients with ICS on final adult height are not known [see Warnings and Precautions (5.14)].
Single-dose intravenous infusion (weight-based dosing) of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months Patients will undergo careful screening to confirm that this treatment is adequate for them. Chemotherapy will be given prior to BE CAR-7 infusion. Patients will then receive a single infusion of the BE CAR-7 cells and will be closely monitored in hospital via blood and bone marrow tests for safety and to check the levels of BE CAR-7 and leukaemia cells. Patients are expected to be in hospital for 4-6 weeks for the BE CAR-7 therapy and the transplant will be scheduled 2-4 weeks after the end of BE CAR7 if leukaemia cells are no longer detectable. Patients will be monitored on the study for 1 year every month for the first 3 months and then every 6 months and then long term in routine clinics.
Adequate studies investigating the carcinogenic potential of capecitabine have not been conducted. Capecitabine was not mutagenic in vitro to bacteria (Ames test) or mammalian cells (Chinese hamster V79/HPRT gene mutation assay). Capecitabine was clastogenic in vitro to human peripheral blood lymphocytes but not clastogenic in vivo to mouse bone marrow (micronucleus test). Fluorouracil causes mutations in bacteria and yeast. Fluorouracil also causes chromosomal abnormalities in the mouse micronucleus test in vivo. 

In studies of fertility and general reproductive performance in female mice, oral capecitabine doses of 760 mg/kg/day (about 2,300 mg/m2/day) disturbed estrus and consequently caused a decrease in fertility. In mice that became pregnant, no fetuses survived this dose. The disturbance in estrus was reversible. In males, this dose caused degenerative changes in the testes, including decreases in the number of spermatocytes and spermatids. In separate pharmacokinetic studies, this dose in mice produced 5’-DFUR AUC values about 0.7 times the corresponding values in patients administered the recommended daily dose.
The present invention is a method and composition for treatment of ischemic, metabolic, congenital, or degenerative disorders of the central or peripheral nervous system. The composition is formed by encapsulation within an implantable biocompatible polymeric device of one or more compounds which have the effect or replacing or stimulating functions of the nervous system. A variety of biocompatible polymers including both biodegradable and non-degradable polymers can be used to form the implants. An essential feature of the composition is linear release, achieved through manipulation of the polymer composition and form. The selection of the shape, size, drug, polymer, and method for implantation are determined on an individual basis according to the disorder to be treated and the individual patient response. A plethora of neurally active substances can be used to treat or manipulate neurological disorders, including Parkinson's Disease, particularly the subset which is refractory or poorly responsive to existing therapies; Alzheimer's Disease; Huntington's Disease; and trauma, such as spinal cord injury.
Beginning 8-10 weeks before radiation therapy, participants receive androgen suppression therapy SC or IM for up to 6 months (at the discretion of the treating physician). Participants then undergo hypofractionated radiation therapy as Group I.
OBJECTIVE: To identify the prevalence of obesity documented within the electronic medical record problem list.
METHODS: We conducted a retrospective cohort study of adult patients with obesity and endometrial cancer receiving care from January 2018 to March 2021 at a single institution. Obesity intervention was defined as receipt of at least one of the following: referral to weight loss clinic, referral to a nutritionist, completion of obesity intervention tab, or documentation of weight loss counseling. Our secondary objectives were to (1) identify the prevalence of completed obesity interventions, (2) identify the number of patients who have achieved weight loss since their initial visit, and (3) identify covariates associated with presence of obesity on problem list, completion of obesity interventions, and weight loss.
RESULTS: We identified 372 patients who met inclusion criteria. Of eligible patients, 202 (54%) had obesity documented on their problem list and 171 (46%) completed at least one obesity intervention. Within our cohort, 195 (52%) patients achieved weight loss from diagnosis or initial clinical encounter at our institution to most recent clinical encounter with median weight loss of 3.9 kg (IQR 1.5-8.0). In the multivariable logistic regressions, patients with obesity on the problem list were approximately twice as likely to have completion of obesity intervention (OR 1.91, 95% CI 1.09, 3.35, p=0.024). Although presence of obesity on the problem list was not associated with weight loss, completion of health maintenance obesity intervention tab in the electronic medical record (Epic) was associated with weight loss (OR 2.77, 95% CI 1.11, 6.89, p=0.03).
CONCLUSIONS: Only half of obese endometrial cancer patients had documentation of obesity within the electronic medical record problem list. The electronic medical record could be leveraged to achieve compliance with weight loss interventions. Further investigation on how the electronic medical record can be optimized to help patients achieve weight loss is needed.
Cerebral ischemia-reperfusion injury (I/RI) is one of the principal pathogenic factors in the poor prognosis of ischemic stroke, for which current therapeutic options to enhance neurological recovery are notably insufficient. Dental pulp stem cell-derived extracellular vesicles (DPSC-EVs) have promising prospects in stroke treatment and the specific underlying mechanisms have yet to be fully elucidated. The present study observed that DPSC-EVs ameliorated the degree of cerebral edema and infarct volume by reducing the apoptosis of neurons. Furthermore, the miRNA sequencing and functional enrichment analysis identified that miR-877-3p as a key component in DPSC-EVs, contributing to neuroprotection and anti-apoptotic effects. Following target prediction and dual-luciferase assay indicated that miR-877-3p interacted with Bcl-2-associated transcription factor (Bclaf1) to play a function. The miR-877-3p inhibitor or Bclaf1 overexpression reversed the neuroprotective effects of DPSC-EVs. The findings reveal a novel therapeutic pathway where miR-877-3p, transferred via DPSC-EVs, confers neuroprotection against cerebral I/RI, highlighting its potential in promoting neuronal survival and recovery post-ischemia.
The cosmetic stick composition comprises a wax component, polymeric organic hydrogen forming substance, a nonionic oil in water emergent and a nonionic water in oil emergent. An oil liquid under standard condition, a water soluble polyvalent 2-9 carbons alkanol with 2-6 hydroxyl groups or a water-soluble polyethylene glycol with 3-20 ethylene oxide units, 6-75 wt.% of water, a nonionic and ionic emulgent or surfactant, a cosmetic or dermatological active ingredient and a solid, water-insoluble particulate filler are also provided. The wax component has fusion point greater than 50[deg] C and is not added in the nonionic oil in water emulgent and the nonionic water in oil emulgent. The nonionic oil in water emulgent has a hydrophilic-lipophilic balance (HLB) value of greater than seven within the oil in water emulgent mixture within an average HLB value of 11-17. The nonionic water in oil emulgent has a HLB value of 1.0-7.0, which forms liquidcrystalline structures with water or with water in the presence of a hydrophilic emulgent, as consistency agents or water binders. The oil liquid under standard condition does not represent a fragrance component and essential oil, where the average solubility parameter of the whole of the contained oils differs from the average solubility parameter of the water in oil emulgent or the water in oil emulgent. The mixture of the polymeric hydrogel-forming substance is excluded from guar gum, locust bean gum and pectin. The total content of nonionic and ionic emulgent or surfactants has a HLB value of greater than 8. A free radical inhibitor substance or a precipitating substance is provided in combination with an UV filter substance. Independent claims are included for: (1) a cosmetic, non-therapeutic method for improving the appearance of the skin, which involves applying a stick composition on the skin, particularly on the skin of the shoulder or face; and (2) a method for producing a cosmetic stick composition, which involves heating and melting wax and oil components with the oil in water and water in oil emulgent at 90-95[deg] C, adding heated water at 90-95[deg] C with the water-soluble effective and ingredients under strong agitation, adding other ingredients, cooling the mixture at a suitable filling temperature, filling into suitable dispenser forms, and solidifying by static cooling without agitating at room temperature. ACTIVITY : Antiseborrheic; Dermatological; antiinflammatory; antibacterial. MECHANISM OF ACTION : None given.
Use of coal tar with narrowband (NB) ultraviolet B (UVB) light (the Goeckermen regimen) is an effective treatment for plaque psoriasis that has become impractical in outpatient care mainly due to the inconvenience and aesthetic concerns of coal tar. This study aims to evaluate the safety, efficacy, and convenience of adding a novel liquor carbonis distillate (LCD) (coal tar) solution to standard NB_UVB phototherapy in adults with chronic plaque psoriasis. Patients will apply LCD solution to half the body, twice daily at home and receive outpatient full-body NB-UVB light therapy 3 times a week for up to 12 weeks. A blinded investigator will grade psoriasis severity of body halves and bilateral target lesions and monitor adverse reactions. Patients will rate their psoriasis symptoms and LCD solution aesthetics. Incorporating an at-home regimen with a novel LCD solution into outpatient NB-UVB light therapy is safe, convenient, and effective and can improve psoriasis more quickly than NB-UVB light therapy alone.
BLOXIVERZ should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents. Doses of BLOXIVERZ should be individualized, and a peripheral nerve stimulator should be used to determine the time of initiation of BLOXIVERZ and should be used to determine the need for additional doses. 

BLOXIVERZ is for intravenous use only and should be injected slowly over a period of at least 1 minute. The BLOXIVERZ dosage is weight-based [see Dosage and Administration (2.2)].

Prior to BLOXIVERZ administration and until complete recovery of normal ventilation, the patient should be well ventilated and a patent airway maintained. Satisfactory recovery should be judged by adequacy of skeletal muscle tone and respiratory measurements in addition to the response to peripheral nerve stimulation.

An anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, should be administered prior to or concomitantly with BLOXIVERZ [see Dosage and Administration (2.4)]
Methods: The study will be a double-blind randomized control trial. Patients will be randomly assigned to receive either intramuscular injection of the lower cervical paraspinous muscles with 1 mL of 0.5% ropivacaine on each side, placebo injections with 1 mL normal saline on each side, or no intervention at all. If randomized to an injection, the investigator and the patient will both be blinded as to the nature of the injection.

The location of the child's pain as well as severity will be assessed immediately prior to intervention and every 10 minutes for 30 minutes. If after 30 minutes relief is insufficient for discharge to home, intravenous treatment will be instituted according to current protocol. Pain will be reassessed at the time of ultimate disposition. The scale used to assess severity will vary based on the child's age.
It is recommended that CellCept Oral Suspension be constituted by the pharmacist prior to dispensing to the patient.

CellCept Oral Suspension should not be mixed with any other medication.

Mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits. There are no adequate and well-controlled studies in pregnant women (see WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and HANDLING AND DISPOSAL). Care should be taken to avoid inhalation or direct contact with skin or mucous membranes of the dry powder or the constituted suspension. If such contact occurs, wash thoroughly with soap and water; rinse eyes with water.

  1. Tap the closed bottle several times to loosen the powder.
  2. Measure 94 mL of water in a graduated cylinder.
  3. Add approximately half the total amount of water for constitution to the bottle and shake the closed bottle well for about 1 minute.
  4. Add the remainder of water and shake the closed bottle well for about 1 minute.
  5. Remove the child-resistant cap and push bottle adapter into neck of bottle.
  6. Close bottle with child-resistant cap tightly. This will assure the proper seating of the bottle adapter in the bottle and child-resistant status of the cap.



Dispense with patient instruction sheet and oral dispensers. It is recommended to write the date of expiration of the constituted suspension on the bottle label. (The shelf-life of the constituted suspension is 60 days.)

After constitution the oral suspension contains 200 mg/mL mycophenolate mofetil. Store constituted suspension at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Storage in a refrigerator at 2° to 8°C (36° to 46°F) is acceptable. Do not freeze. Discard any unused portion 60 days after constitution.